Blueprint Medicines price target lowered to $151 from $153 at Wells Fargo
The Fly

Blueprint Medicines price target lowered to $151 from $153 at Wells Fargo

Wells Fargo analyst Derek Archila lowered the firm’s price target on Blueprint Medicines (BPMC) to $151 from $153 on slightly lower estimates, while keeping an Overweight rating on the shares. The firm remains bullish on shares as it expects an above-consensus guide for Ayvakit for FY25 plus POS BLU-808 Ph1 data in early 2025 to offer upside.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App